Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Revenue of Tango Therapeutics, Inc. (TNGX)
Revenue in 2023 (TTM): $36.53 M
According to Tango Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $36.53 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tango Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $36.53 M | $-78,671,000 | $-111,758,000 | $-101,610,000 | $-101,744,000 |
| 2022 | $24.86 M | $20.83 M | $-109,463,000 | $-108,122,000 | $-108,176,000 |
| 2021 | $37.04 M | $35.08 M | $-57,293,000 | $-57,943,000 | $-58,235,000 |
| 2020 | $7.66 M | $6.03 M | $-51,482,000 | $-51,972,000 | $-51,864,000 |
| 2019 | $24.65 M | $-7,625,000 | $-14,519,000 | $-14,095,000 | $-14,095,000 |